Advertisement

Archives of Gynecology and Obstetrics

, Volume 299, Issue 5, pp 1399–1404 | Cite as

Compare two different usages of FRD for detecting high-grade cervical lesions and invasive cancer

  • Yuping Dai
  • Lirong Wang
  • Donghong LiEmail author
Gynecologic Oncology
  • 41 Downloads

Abstract

Objective

To evaluate two usages of the folate receptor-mediated staining solution (FRD) for detecting high-grade cervical lesions and invasive cancer, and compared with cytology test (TCT) and human papillomavirus (HPV) testing.

Methods

FRD sampling and FRD direct staining methods were used for detecting high-grade cervical lesions and invasive cancer. As a comparison, TCT and HPV testing were also applied for screening high-grade cervical lesions and invasive cancer. The sensitivity and specificity of TCT, HPV testing, and staining results of FRD were analyzed by the SPSS software.

Results

In this study, 317 patients with biopsy were collected. The positive rate of FRD sampling method was 35.33% (112/317), and positive rate of FRD direct staining was 48.90% (155/317). Area under the curve (AUC) of TCT, HPV testing, FRD sampling and FRD direct staining were 0.53, 0.55, 0.58, and 0.75, respectively. The sensitivity of TCT, HPV, FRD sampling and FRD direct staining was 69.72%, 97.25%, 64.22% and 81.65%, respectively, and the specificity was 37.98%, 12.98%, 79.81% and 68.27%, respectively.

Conclusion

Compared with TCT and HPV testing, two usages of FRD methods have compatible sensitivity and high specificity to detect high-grade cervical lesions and invasive cancer. FRD direct staining may be comfortable for routine cervical cancer screening

Keywords

Folate receptor-mediated staining solution (FRD) High-grade cervical lesions Invasive cancer Cytology test Human papillomavirus testing 

Notes

Author contributions

DHL: guarantor of integrity of the entire study, study concepts and design, definition of intellectual content, literature research, statistical data analysis, manuscript preparation, editing, and review. YPD: clinical studies and studies. LRW: clinical studies and data acquisition.

Funding

This study was not funded.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics, 2012. CA Cancer J Clin 61:69–90CrossRefGoogle Scholar
  2. 2.
    Waggoner SE (2003) Cervical cancer. Lancet 361:2217–2225CrossRefGoogle Scholar
  3. 3.
    Hu Z, Zhu D, Wang W et al (2015) Genome-wide profiling of HPV integration in cervical cancer identifies clustered genomic hot spots and a potential microhomology-mediated integration mechanism. Nat Genet 47:158CrossRefGoogle Scholar
  4. 4.
    Organization WH (2005) IARC handbooks of cancer prevention, vol 10. Cervix cancer screening, pp 117–120.Google Scholar
  5. 5.
    Berkhof J, Meijer CJ (2007) Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer. N Engl J Med 358:642 (author reply 3) Google Scholar
  6. 6.
    Naucler P, Ryd W, Törnberg S et al (2008) Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 357:1589CrossRefGoogle Scholar
  7. 7.
    Nanda K, Mccrory DC, Myers ER et al (2000) Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 132:810CrossRefGoogle Scholar
  8. 8.
    Staples M (2014) HPV-based screening for prevention of invasive cervical cancer. Lancet 383:1294CrossRefGoogle Scholar
  9. 9.
    Zhang CH, Xue XL, Dang RF, Gynecology DO (2014) Application value of folate receptor mediated FRD in diagnosis of cervical intraepithelial neoplasia and cancer. Chin J Lab Diagn 8:7830–7836Google Scholar
  10. 10.
    Lu MH, Hu LY, Du XX et al (2014) An special epithelial staining agents: folic acid receptor-mediated diagnosis (FRD) effectively and conveniently screen patients with cervical cancer. Int J Clin Exp Med 8:7830Google Scholar
  11. 11.
    Anonymous (2010) The 1991 bethesda system for reporting cervical/vaginal cytological diagnoses. Diagn Cytopathol 9:235–246Google Scholar
  12. 12.
    Bosch FX, Broker TR, Forman D et al (2013) Comprehensive control of human papillomavirus infections and related diseases. Vaccine 31(Suppl 5):F1CrossRefGoogle Scholar
  13. 13.
    Goodman A (2015) HPV testing as a screen for cervical cancer. BMJ 350:h2372CrossRefGoogle Scholar
  14. 14.
    Davey E, Denton (2007) Accuracy of reading liquid based cytology slides using the ThinPrep Imager compared with conventional cytology: prospective study. BMJ 335:31–35CrossRefGoogle Scholar
  15. 15.
    Akamatsu S, Kodama S, Himeji Y, Ikuta N, Shimagaki N (2012) A comparison of liquid-based cytology with conventional cytology in cervical cancer screening. Acta Cytol 56:370–374CrossRefGoogle Scholar
  16. 16.
    Girianelli VR, Thuler LC, Szklo M et al (2006) Comparison of human papillomavirus DNA tests, liquid-based cytology and conventional cytology for the early detection of cervix uteri cancer. Eur J Cancer Prev 15:504–510CrossRefGoogle Scholar
  17. 17.
    Kitchener HC, Gilham C, Sargent A et al (2011) A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer 47:864CrossRefGoogle Scholar
  18. 18.
    Ronco G, Cuzick J, Pierotti P et al (2007) Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ 335:28CrossRefGoogle Scholar
  19. 19.
    Low PS, Henne WA, Doorneweerd DD (2008) Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res 41:120–129CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Obstetrics and Gynecology, Affiliated Guangren Hospital, School of MedicineXi’an Jiaotong UniversityXi’anChina
  2. 2.Department of Gynecology Oncology, The Affiliated Shaanxi Provincial Cancer Hospital, School of MedicineXi’an Jiaotong UniversityXi’anChina

Personalised recommendations